Stem-cell and bone-marrow transplantation: cells, donors, recovery and outcomes

Understand the cells and process before comparing outcomes

The cell source and the donor relationship are separate choices

Marrow is collected from the pelvic bone under anesthesia. Apheresis collects circulating blood-forming cells after medicines increase their number, returning the remaining blood. Cord blood comes from a collected unit. Cell source and donor relationship are separate choices, made in the context of disease, prior treatment and health.[3]

Matching requires specific testing

HLA typing uses blood or a cheek swab. The team compares family donors, unrelated donors and cord-blood units. A close relative is not automatically suitable. Full, partial and haploidentical matches are different options, so lacking a fully matched donor need not rule out transplantation.[4]

These blood-forming cells have a specific therapeutic role

This guide concerns blood formation, separate from solid-organ replacement or retail regenerative injections. Genetically modified autologous HSC therapies add an engineering step to collected cells. The EBMT chapter describes gene addition or editing to change cell function. Those therapies need their own evidence and safety assessment; ordinary autologous transplantation does not itself mean gene editing.[5]

Engraftment begins a longer period of care

Infused cells travel to the marrow, and blood counts are checked frequently. Recovery varies; monitoring may continue for a year or longer. Follow the transplant team’s infection-prevention and complication instructions. Blood-count improvement does not itself mean that infection risk, immune recovery or all treatment effects have resolved.[2]

Risks include more than graft failure

Conditioning and transplantation can cause infection, bleeding, mouth sores, fatigue and organ injury. Later effects may include infertility or secondary cancers. Allogeneic transplantation adds GVHD risk: donor white blood cells can attack skin, gut, liver or other tissues. GVHD and graft rejection describe opposite directions of immune attack. Discuss the anticipated complications, fertility concerns and follow-up plan before treatment; the risks are not identical for every transplant.[1]

Published questions

Autologous transplantation: a myeloma comparison

DETERMINATION randomized 722 adults aged eighteen to sixty-five with newly diagnosed symptomatic myeloma to a triplet-treatment strategy with or without high-dose melphalan and autologous transplantation. Both groups received lenalidomide maintenance until progression or unacceptable effects. At median follow-up of seventy-six months, median progression-free survival was 67.5 months with transplantation and 46.2 without. Five-year overall survival was similar, and no overall survival benefit was observed. Grade-three-or-higher treatment-related adverse events were more common with transplantation. This comparison concerns that treatment sequence and population, not every myeloma regimen or every older adult.[6]

Allogeneic transplantation: an older-adult MDS study

BMT CTN 1102 enrolled 384 transplant-eligible adults aged fifty to seventy-five with higher-risk de novo myelodysplastic syndrome. Assignment depended on finding a suitable matched donor, rather than random allocation. The donor strategy used reduced-intensity transplantation; the comparison involved hypomethylating therapy or supportive care. Adjusted three-year survival was 47.9% in the donor arm and 26.6% without a donor. Adjustment addresses measured differences but cannot remove every bias from donor-based assignment. This result supports a specific clinical comparison; it is not the survival probability of every patient who receives a transplant.[7]

Lower intensity has benefits and tradeoffs

BMT CTN 0901 randomized 272 adults aged eighteen to sixty-five with AML or MDS, low marrow blast counts and a matched donor to myeloablative or reduced-intensity conditioning. At median follow-up of fifty-one months, four-year transplant-related mortality was higher with myeloablative conditioning, but relapse was substantially higher with reduced intensity. Overall survival favored myeloablative conditioning in this population eligible for either approach. Lower toxicity and better disease control can pull in different directions. The result does not establish the best intensity for someone unable to tolerate the more intensive regimen.[8]

A donor-source trial had different primary and secondary results

BMT CTN 1101 randomized 368 adults aged eighteen to seventy with responsive lymphoma or acute leukemia in remission to double unrelated cord blood or haploidentical relative bone marrow, using specified reduced-intensity regimens. The primary two-year progression-free survival comparison was not significant: 35% versus 41%, respectively. Secondary overall survival favored haploidentical marrow, with higher nonrelapse mortality after cord blood. These results should retain the distinction between primary and secondary endpoints. They do not establish that every cord-blood approach is inferior or that every partly matched donor is preferable.[9]

GVHD prevention is part of the treatment strategy

BMT CTN 1703 randomized 431 adults receiving reduced-intensity allogeneic transplantation for blood cancers to two GVHD-prevention regimens. The trial used matched related or matched or narrowly mismatched unrelated donors. At one year, adjusted GVHD-free, relapse-free survival was 52.7% with a cyclophosphamide-based combination and 34.9% with tacrolimus plus methotrexate. This composite counted severe acute GVHD, chronic GVHD needing systemic immunosuppression, relapse or progression, and death. Overall survival, relapse and engraftment did not differ substantially. The trial supports that regimen comparison, not unsupervised medication changes or elimination of GVHD risk.[10]

A useful consultation keeps the comparison explicit

Ask about the intended outcome, alternatives, recovery, donor access and risks of waiting. Your disease status and health affect the balance; trial averages cannot determine an individual outcome.[3]

References

1. Stem Cell and Bone Marrow Transplants for Cancer

   Agency condition or prevention explanation

   National Cancer Institute · Content/publication date: 2023-10-05
   Accessed: 2026-10-14 UTC · Selected original substantive page passages inspected
   Cited sections: Blood-cell role; autologous/allogeneic categories; short/late effects; GVHD direction; displayed update date

   Source’s simplified acute/chronic calendar distinction and fixed home-return timeline are not adopted. No universal transplant success estimate.

2. Treatments for Blood Disorders

   Agency condition or prevention explanation

   National Heart, Lung, and Blood Institute · Content/publication date: 2022-03-24
   Accessed: 2026-10-14 UTC · Selected original substantive page passages inspected
   Cited sections: Blood and bone-marrow transplant section; IV delivery; conditioning; own/donor cells; count monitoring; infection and follow-up

   Displayed last update. General transplant process only; blood-transfusion risk figures elsewhere on page are not used.

3. About Transplantation

   Agency condition or prevention explanation

   Health Resources and Services Administration, Blood Stem Cell · Content/publication date: not stated
   Accessed: 2026-10-14 UTC · Selected original substantive page passages inspected
   Cited sections: Types and sources; collection; conditioning; cell infusion; recovery; treatment questions; displayed last reviewed month

   Last reviewed February 2026, month precision retained. Registry totals and universal time-to-home estimates are not used.

4. What is HLA? HLA Basics, Typing and Matching Overview

   Official transplant program patient explanation

   National Marrow Donor Program · Content/publication date: not stated
   Accessed: 2026-10-14 UTC · Selected original substantive page passages inspected
   Cited sections: HLA typing; full/partial/haploidentical donor categories; detailed testing and family/unrelated/cord options

   No publication or update date verified. Current retrieval is not a publication date. Simplified categories are used without asserting a universal HLA matching threshold.

5. Biological Properties of Hematopoietic Stem Cells: Scientific Basis for Hematopoietic Cell Transplantation

   Professional handbook chapter

   Alessandro Aiuti, Serena Scala and Christian Chabannon; EBMT Handbook, 8th edition · Content/publication date: 2024
   Accessed: 2026-10-14 UTC · Selected full original publisher chapter passages inspected
   Cited sections: Sections 7.1–7.2 blood lineage/self-renewal; section 7.6 genetically modified autologous HSC and engineering distinctions; first online date

   Dated professional narrative handbook chapter, not an original clinical trial or exhaustive 2026 effectiveness review. Bookshelf PDF/page challenged; original publisher full text was available. No named gene-therapy approval or current product label claim.

6. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

   Randomized controlled trial

   Paul G. Richardson and colleagues; DETERMINATION investigators · Content/publication date: 2022
   Accessed: 2026-10-14 UTC · Original indexed abstract and original abstract repeated by investigators at Dana-Farber inspected; direct PubMed/publisher/PMC unavailable; no independent full-text appraisal
   Cited sections: Original abstract; 722 adults 18–65; RVD/ASCT sequences; maintenance in both arms; median follow-up 76 months; PFS, OS and grade 3+ harms

   Publisher original indexed field verifies online June 5, 2022; July 14 issue. Dana-Farber repeats original abstract, not an independent source or replication. No overall survival benefit observed at reported follow-up; no current-regimen superiority assumption.

7. Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50–75 Years of Age With Advanced Myelodysplastic Syndrome

   Prospective biologic assignment trial

   Ryotaro Nakamura and colleagues; BMT CTN 1102 · Content/publication date: 2021
   Accessed: 2026-10-14 UTC · Original indexed methods/results and transplant-network study summary inspected; direct PubMed/PMC unavailable; no independent full-text appraisal
   Cited sections: Original indexed methods/results; 384 participants; donor-based assignment; adjusted three-year OS; eligibility and alternative treatment; publisher online date

   Original publisher fields give online June 9 and print October 20, 2021. Not randomized. Adjusted donor-strategy intention-to-treat outcomes are not universal recipient survival; NMDP summary belongs to the same study.

8. Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in AML and MDS: Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial

   Randomized controlled trial long term follow up

   Bart L. Scott and colleagues · Content/publication date: 2021
   Accessed: 2026-10-14 UTC · Original PubMed abstract and bibliographic date inspected; no independent full-text appraisal
   Cited sections: Original abstract; 272 adults 18–65; low blasts; matched donors; median follow-up 51 months; four-year TRM, relapse and survival tradeoff

   Online February 26, June 2021 issue. Follow-up of one randomized cohort, not independent replication. Eligibility for both regimens is retained; no personal conditioning recommendation.

9. Double unrelated umbilical cord blood versus HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial

   Randomized controlled trial

   Ephraim J. Fuchs and colleagues · Content/publication date: 2021
   Accessed: 2026-10-14 UTC · Original PubMed methods/results abstract and selected original indexed result passages inspected; no independent full-text appraisal
   Cited sections: Original abstract; 368 adults 18–70; responsive lymphoma/remission acute leukemia; source-specific prophylaxis; primary two-year PFS versus secondary OS/nonrelapse mortality; issue date

   Verified January 21, 2021 issue date. Double cord blood and haplo marrow included different GVHD-prevention regimens, so comparison is not an isolated cell-source effect. Primary endpoint not significant; secondary outcomes retained as such.

10. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis

    Randomized controlled trial

    Javier Bolaños-Meade and colleagues; BMT CTN 1703 investigators · Content/publication date: 2023
    Accessed: 2026-10-14 UTC · Original PubMed methods/results abstract and official NHLBI study description inspected; no independent full-text appraisal
    Cited sections: Original methods/results; 431 adults; related matched or unrelated matched/7-of-8; reduced intensity; one-year composite definition and adjusted results; separate outcomes

    June 22, 2023 issue. Related NHLBI study summary is the same cohort, not an independent replication. No dosing schedule, drug label or individualized regimen is offered; selected trial comparison only.

Scope & review

Population

General readers considering hematopoietic transplantation; selected adult hematologic cancer populations in trials; no pediatric or every nonmalignant-condition extrapolation

Exposure or intervention

Conventional autologous/allogeneic HCT; marrow/peripheral/cord sources; matching, conditioning, engraftment and GVHD prevention; engineered HSC therapy described only as a boundary

Comparison

Source-specific nontransplant therapy, conditioning intensity, donor strategies or GVHD-prevention regimens; trials do not all compare transplant with no transplant

Outcomes

Blood-count recovery, survival, progression/relapse, GVHD composites, toxicity and longer recovery; no universal success rate

Timeframe

Process through long-term care; selected trial endpoints one to four years and median follow-up through seventy-six months; sources checked October 14, 2026

Jurisdiction

US NIH/HRSA/NMDP patient resources and international EBMT chapter; original trials have their own eligibility and settings; no global insurance, legal or product approval claim

Selected-source educational explanation. Official guidance, original study findings and editorial interpretation are distinguished. No exhaustive search, independent systematic synthesis or qualified medical review has been completed.

Sources checked on their individual access dates. Selected sources were checked; ongoing surveillance and qualified review have separate statuses on the coverage page.

What this article still leaves open

• Qualified clinical, lived-experience and methods review remains pending; no formal evidence grade or automatic updates.
• No exhaustive transplantation guideline, disease-by-disease treatment recommendation or individual eligibility assessment was completed.
• Current regimens, alternative donors, longer follow-up and patient-specific risk may differ from the selected trial comparisons.
• Several original full clinical reports were inaccessible; use is bounded to inspected original methods/results abstracts, indexed passages and explicitly related investigator/network summaries.

Related reading

Explore the topic map

Browse the health domains connected to this article. The map also identifies topics whose articles remain unwritten.